Your health and wellness news reporter from Liechtenstein
Provided by AGP
AGP Picks
View all
Perspectify News
Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Filter
Press releases
Publish your press release
May. 5, 2026
CEO Insight’s Investors Guide Examines Evolving Investment Strategies Across Global Financial Markets
EIN Presswire
Featuring senior industry voices, the issue explores cross-border investment, financial innovation and the growing importance of trust in global markets.
Mar. 30, 2026
4BIO Capital strengthens investment leadership with appointment of Therese Liechtenstein as Partner and Tetsu Maruyama as Venture Partner
GlobeNewswire, Inc.
Thera Liechtenstein brings extensive biotech investment and company‑building experience to new role as Partner at 4BIO Capital Tetsu Maruyama, former Head of Drug Discovery at Takeda Pharmaceuticals, appointed as Venture Partner London, United...
Apr. 22, 2026
Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
GlobeNewswire, Inc.
New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused on pediatric diseases; Ojemda® (tovorafenib) represents a rare achievement that reinforces the urgent...
Apr. 3, 2026
Virella Files European Patent Application for Novel SIRT6 Small-Molecule Activators
EIN Presswire
Liechtenstein-based biotech company reports significant lifespan extension in C. elegans and advances toward preclinical development with CRO partners SCHAAN, LIECHTENSTEIN, April 3, 2026 /EINPresswire.com/ -- Virella Ltd, a European biotech...
Jun. 9, 2025
Liechtenstein Reaffirms Global Leadership in Stability and Philanthropy
EIN Presswire
LONDON, UNITED KINGDOM, June 9, 2025 /EINPresswire.com/ -- The Principality of Liechtenstein continues to demonstrate its exceptional standing on the global stage, with two recent developments underscoring its strength in both financial...
Jul. 28, 2025
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
GlobeNewswire, Inc.
CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted...
Video Stories
Discover Affinity Group Publishing
Sign up for:
Health Monitor Liechtenstein
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.
Explore More
